Hibercell

Hibercell company information, Employees & Contact Information

Explore related pages

Related company profiles:

HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both completing Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently in Phase 2 clinical development, modulates the anti-tumor innate immune response.

Company Details

Employees
27
Address
619 West 54th Street,
Phone
212-601-2800
Email
co****@****ell.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
New York, New York
Looking for a particular Hibercell employee's phone or email?

Hibercell Questions

News

Prostitution scandal hits taxpayer-backed Irish genome venture - The Times

Prostitution scandal hits taxpayer-backed Irish genome venture The Times

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies - Frontiers

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies Frontiers

Merck partners with HiberCell for Phase Ib renal carcinoma trial - Clinical Trials Arena

Merck partners with HiberCell for Phase Ib renal carcinoma trial Clinical Trials Arena

HiberCell Announces Acquisition of Biothera Pharmaceuticals' Imprime PGG Program - PR Newswire

HiberCell Announces Acquisition of Biothera Pharmaceuticals' Imprime PGG Program PR Newswire

HiberCell Appoints Jonathan Lanfear as Chief Operating Officer - citybiz

HiberCell Appoints Jonathan Lanfear as Chief Operating Officer citybiz

HiberCell launches with $60M+ to combat cancer relapse and metastasis - Fierce Biotech

HiberCell launches with $60M+ to combat cancer relapse and metastasis Fierce Biotech

HiberCell buys Genuity Science for $100 million - The Business Journals

HiberCell buys Genuity Science for $100 million The Business Journals

New York biotech debuts, targeting dormant metastatic cancer cells - statnews.com

New York biotech debuts, targeting dormant metastatic cancer cells statnews.com

HiberCell - The Pharma Letter

HiberCell The Pharma Letter

HiberCell’s Genuity buyout brings $100M, plus alliances with Ionis and AbbVie - MedCity News

HiberCell’s Genuity buyout brings $100M, plus alliances with Ionis and AbbVie MedCity News

Dose Escalation Complete in Kidney Cancer Trial of HC-7366 Plus Welireg - CUREtoday.com

Dose Escalation Complete in Kidney Cancer Trial of HC-7366 Plus Welireg CUREtoday.com

Prostate Cancer Highlights From AUA 2025 - Medscape

Prostate Cancer Highlights From AUA 2025 Medscape

FDA Fast Tracks HC-7366 in Relapsed/Refractory Acute Myeloid Leukemia - Targeted Oncology

FDA Fast Tracks HC-7366 in Relapsed/Refractory Acute Myeloid Leukemia Targeted Oncology

A Promising New Approach Targets Dormant Yet Deadly Cancer Cells - Montefiore Einstein Now

A Promising New Approach Targets Dormant Yet Deadly Cancer Cells Montefiore Einstein Now

New York Biotech Raises $61 Million To Keep Cancer Cells Dormant, Bucking Conventional Treatments - Forbes

New York Biotech Raises $61 Million To Keep Cancer Cells Dormant, Bucking Conventional Treatments Forbes

Pioneering the Discovery and Development of Novel Therapeutics to Prevent Metastasis - Nature

Pioneering the Discovery and Development of Novel Therapeutics to Prevent Metastasis Nature

Genuity Science acquired by oncology research outlet HiberCell - Silicon Republic

Genuity Science acquired by oncology research outlet HiberCell Silicon Republic

Triple Negative Breast Cancer Market Outlook 2034 - Clinical - openPR.com

Triple Negative Breast Cancer Market Outlook 2034 - Clinical openPR.com

HC-5404 improves response to VEGFR-TKIs and ICIs in preclinical models - BioWorld MedTech

HC-5404 improves response to VEGFR-TKIs and ICIs in preclinical models BioWorld MedTech

Triple-Negative Breast Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies | DelveInsight - GlobeNewswire

Triple-Negative Breast Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies | DelveInsight GlobeNewswire

DNA analysis firm Genuity Science bought by HiberCell - RTE.ie

DNA analysis firm Genuity Science bought by HiberCell RTE.ie

DNA analysis firm Genuity Science is sold to HiberCell - The Irish Independent

DNA analysis firm Genuity Science is sold to HiberCell The Irish Independent

Genetic harvesting firm Genuity Science records millions in revenues as it winds down - Business Post

Genetic harvesting firm Genuity Science records millions in revenues as it winds down Business Post

Top Hibercell Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant